Later COMBI‐AD trial demonstrated dual‐targeted therapy of Dabrafenib plus Trametinib (D + T) significantly reduced the risks of recurrence and metastasis for Stage III BRAF‐mutant melanoma.10 The gene discussed is BRAF; the disease is melanoma.